China’s Hybrid Economy: What to Do about BGI?

Anna Puglisi

February 2, 2024

As the U.S. government considers banning genomics companies from China in the Biosecure Act, it opens a broader question of how the U.S. and other market economies should deal with China’s national champions. This blog post provides an overview of BGI and how China’s industrial policy impacts technology development.

Related Content

CSET's Anna Puglisi and Andrew Imbrie discuss actions democracies can take to shape the development of biotechnology. Read More

CSET Senior Fellow Anna Puglisi testified before the Senate Select Committee on Intelligence on "Beijing's Long Arm: Threats to U.S. National Security." She offered recommendations to counter China's S&T collection efforts. Read More


The Huawei Moment

July 2021

For the first time, a Chinese company—Huawei—is set to lead the global transition from one key national security infrastructure technology to the next. How did Washington, at the beginning of the twenty-first century, fail to… Read More